Baird 'Incrementally Positive' on Intercept (ICPT) Amid OCA Priority Review and Competitor Blow Up
Tweet Send to a Friend
Baird analyst Brian Skorney reiterated an Outperform rating and $227.00 price target on Intercept Pharmaceuticals (NASDAQ: ICPT), saying they are ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
